In this phase III open label, controlled clinical trial patients with unresectable or
metastatic soft-tissue sarcoma after failure of anthracycline-containing first line therapy
or with contraindications to these drugs and CD13 positivity in central histology (grade >/=
1+) are treated to evaluate whether tTF-NGR in combination with standard trabectedin
chemotherapy prolongs progression-free survival (according to iRECIST), as compared with
trabectedin alone. Further objectives are to evaluate the efficacy of tTF-NGR in combination
with standard trabectedin chemotherapy with respect to the response rate and overall survival
as well as to assess the safety profile of tTF-NGR combined with trabectedin. Before the
randomized phase III part of the study, there will be a safety run-in part. The final dose of
tTF-NGR established as safe in this safety run-in part will be used for the randomized
(parallel 1:1; Arm 1: standard trabectedin, Arm 2: standard trabectedin plus tTF-NGR) phase
III part of this trail.